Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update
November 7, 2016 4:05 PM ESTNOVATO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended September 30, 2016.
Based on recent discussions with the FDA, we now plan to file for US approval of KRN23 in the second half of 2017, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. We expect continued clinical and regulatory progress across all of our programs, including filings for rhGUS and... More
